Cargando…

Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: We conducted a systematic review and meta-analysis to clarify the incidence and risk of cardiotoxicity associated with bortezomib in cancer patients. METHODS: Databases from PubMed, Web of Science and abstracts presented at ASCO meeting up to July 31, 2013 were searched to identify relev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Yi, Yin, Jin, Wei, Jia, Shang, Zhen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906186/ https://www.ncbi.nlm.nih.gov/pubmed/24489948 http://dx.doi.org/10.1371/journal.pone.0087671

Ejemplares similares

Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma
por: Paterek, Aleksandra, et al.
Publicado: (2023)

Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy
por: Meseeha, Marcelle G., et al.
Publicado: (2015)

Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis
por: Lu, Yajie, et al.
Publicado: (2023)

Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity
por: Ramji, Kavita, et al.
Publicado: (2022)

Statin Use Is Associated with Reduced Risk of Haematological Malignancies: Evidence from a Meta-Analysis
por: Yi, Xiao, et al.
Publicado: (2014)

Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and meta-analysis
por: Jin, Hao, et al.
Publicado: (2023)

Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity
por: Diwadkar, Sachin, et al.
Publicado: (2016)

Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review
por: Siaravas, Konstantinos C., et al.
Publicado: (2023)

Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol
por: Cantadori, Lucas Oliveira, et al.
Publicado: (2022)

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials
por: Smith, Lesley A, et al.
Publicado: (2010)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

Bortezomib-based vs non-bortezomib-based post-transplantation treatment in multiple myeloma patients: a systematic review and meta-analysis of Phase III randomized controlled trials
por: Liu, Xiaoping, et al.
Publicado: (2015)

Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis
por: Yang, Xinyu, et al.
Publicado: (2021)

Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis
por: Zhang, Meilin, et al.
Publicado: (2022)

A systematic review of the cardiotoxicity of methadone
por: Alinejad, Samira, et al.
Publicado: (2015)

Risk, Incidence, and Mortality of Breast Cancer in Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
por: Deng, Jian, et al.
Publicado: (2022)

The risk factors for herpes zoster in bortezomib treatment in patients with multiple myeloma
por: Yi, Yang-Seon, et al.
Publicado: (2010)

Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis
por: Soares, L.R., et al.
Publicado: (2023)

Bortezomib-based treatment for multiple myeloma patients with renal impairment: A systematic review and meta-analysis of observational studies
por: Zhu, Wanqiu, et al.
Publicado: (2016)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials
por: Jin, Chengwei, et al.
Publicado: (2023)

Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report
por: Yuan, Zhen-gang, et al.
Publicado: (2009)

The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review
por: Conway, Aaron, et al.
Publicado: (2015)

Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis
por: Ye, Ziqi, et al.
Publicado: (2019)

Incidence and risk factors associated with development of clinical cardiotoxicity in dogs receiving doxorubicin
por: Hallman, Briana E., et al.
Publicado: (2019)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology
por: Chung, Robin, et al.
Publicado: (2020)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis
por: Kim, Jean, et al.
Publicado: (2021)

Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta‐analysis
por: Wu, Hongxiao, et al.
Publicado: (2022)

Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis
por: Leong, Siew Lian, et al.
Publicado: (2017)

Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
por: Alhussein, Muhammad Mustafa, et al.
Publicado: (2021)

Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis
por: Goulas, Kyriakos, et al.
Publicado: (2023)

Re: Arcuri and Americo “Treatment of relapsed/refractory multiple myeloma in the bortezomib and lenalidomide era: a systematic review and network meta-analysis”
por: Davies, Faith E., et al.
Publicado: (2022)

A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors
por: Jin, Ying, et al.
Publicado: (2020)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

The effectiveness and harms of bortezomib in combination with chemotherapy for mantle cell lymphoma: A protocol for systematic review and meta-analysis
por: Wang, Xiaoxia, et al.
Publicado: (2020)

Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review
por: Chan, Stefanie Ho Yi, et al.
Publicado: (2023)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Atrial cardiomyopathy and incident ischemic stroke risk: a systematic review and meta-analysis
por: Guo, Jiahuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2qs38u5tj081id4lbahgtpqtmu